Literature DB >> 21249615

Aldosterone producing adrenal adenomas are characterized by activation of calcium/calmodulin-dependent protein kinase (CaMK) dependent pathways.

S Sackmann1, U Lichtenauer, I Shapiro, M Reincke, F Beuschlein.   

Abstract

Primary aldosteronism is the most prevalent cause of secondary hypertension. However, insights in pathophysiological mechanisms resulting in autonomous aldosterone secretion are limited. Although transcriptional regulators of aldosterone synthase (CYP11B2) including calcium-binding calmodulin kinase (CaMK) dependent pathways have been defined in vitro, it remains uncertain whether these mechanisms play a role in the context of dysregulated steroidogenesis in aldosterone producing adrenadenomas. Thus, we compared expression and activation of key components of CaMK pathways in aldosterone producing adenomas (APAs) with normal adrenals glands (NAGs). As expected, aldosterone synthase expression in APAs was significantly higher in comparison to NAGs, suggesting transcriptional activation as a contributing factor of aldosterone excess. Along the same line, CaMKI was significantly upregulated in APAs on the mRNA and protein level. Furthermore, immunohistochemistry revealed nuclear localization of CaMKI in these tumors. The phosphorylation of CREB, a target protein for CaMKI was increased, which could represent a further stimulation of aldosterone synthase transcription. In summary, this study provides indirect evidence for a causative involvement of the CaM kinase signaling pathway in human aldosterone producing adenomas. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21249615     DOI: 10.1055/s-0030-1269899

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  8 in total

1.  Potassium channel mutant KCNJ5 T158A expression in HAC-15 cells increases aldosterone synthesis.

Authors:  Kenji Oki; Maria W Plonczynski; Milay Luis Lam; Elise P Gomez-Sanchez; Celso E Gomez-Sanchez
Journal:  Endocrinology       Date:  2012-02-07       Impact factor: 4.736

2.  Hypomethylation of CYP11B2 in Aldosterone-Producing Adenoma.

Authors:  Yoko Yoshii; Kenji Oki; Celso E Gomez-Sanchez; Haruya Ohno; Kiyotaka Itcho; Kazuhiro Kobuke; Masayasu Yoneda
Journal:  Hypertension       Date:  2016-10-17       Impact factor: 10.190

3.  Mutated KCNJ5 activates the acute and chronic regulatory steps in aldosterone production.

Authors:  Namita G Hattangady; Shigehiro Karashima; Lucy Yuan; Daniela Ponce-Balbuena; José Jalife; Celso E Gomez-Sanchez; Richard J Auchus; William E Rainey; Tobias Else
Journal:  J Mol Endocrinol       Date:  2016-04-20       Impact factor: 5.098

Review 4.  Regulation of adrenocortical steroid hormone production by RhoA-diaphanous 1 signaling and the cytoskeleton.

Authors:  Marion B Sewer; Donghui Li
Journal:  Mol Cell Endocrinol       Date:  2012-11-24       Impact factor: 4.102

5.  Endoplasmic Reticulum Chaperone Calmegin Is Upregulated in Aldosterone-Producing Adenoma and Associates With Aldosterone Production.

Authors:  Kiyotaka Itcho; Kenji Oki; Celso E Gomez-Sanchez; Elise P Gomez-Sanchez; Haruya Ohno; Kazuhiro Kobuke; Gaku Nagano; Yoko Yoshii; Ryuta Baba; Noboru Hattori; Masayasu Yoneda
Journal:  Hypertension       Date:  2019-12-23       Impact factor: 10.190

6.  Calcium-calmodulin kinase I cooperatively regulates nucleocytoplasmic shuttling of CCTα by accessing a nuclear export signal.

Authors:  Marianna Agassandian; Bill B Chen; Roopa Pulijala; Leah Kaercher; Jennifer R Glasser; Rama K Mallampalli
Journal:  Mol Biol Cell       Date:  2012-05-23       Impact factor: 4.138

Review 7.  Aldosterone-Regulated Sodium Transport and Blood Pressure.

Authors:  Akaki Tsilosani; Chao Gao; Wenzheng Zhang
Journal:  Front Physiol       Date:  2022-02-07       Impact factor: 4.566

8.  Vitamin D receptor, an important transcription factor associated with aldosterone-producing adenoma.

Authors:  Changlong Bi; Bo Li; Lili Du; Lishan Wang; Yingqi Zhang; Zhifeng Cheng; Aixia Zhai
Journal:  PLoS One       Date:  2013-12-20       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.